

# *Pharmaceutical Salts and Co-crystals*

Edited by

**Johan Wouters**

*University of Namur, Namur, Belgium*

**Luc Quéré**

*UCB S.A., Brussels, Belgium*

**RSC Publishing**

# Contents

<b>Chapter 1</b>	<b>Pharmaceutical Salts and Co-crystals: Retrospect and Prospects</b>	<b>1</b>
	<i>Gautam R. Desiraju</i>	
	Acknowledgement	6
	References	6
<b>Chapter 2</b>	<b>Fundamental Aspects of Salts and Co-crystals</b>	<b>9</b>
	<i>Andrew D. Bond</i>	
2.1	Introduction	9
2.2	Definitions: Salts and Co-crystals	10
2.3	Supramolecular Chemistry, Intermolecular Interactions and Crystal Packing	12
2.3.1	Supramolecular Synthons	13
2.3.2	The Cambridge Structural Database	14
2.3.3	Supramolecular Yield	17
2.4	Design Strategies for Salts and Co-crystals	18
2.4.1	Synthon Hierarchy and Synthon Interference	18
2.4.2	Ternary and Quaternary Co-crystals	22
2.4.3	Salts or Co-crystals?	24
2.5	Concluding Remarks	26
	References	27
<b>Chapter 3</b>	<b>Role of Fluorine in Weak Interactions in Co-crystals</b>	<b>29</b>
	<i>Seetha Lekshmi Sunil, Susanta K. Nayak, Venkatesha R. Hathwar, Deepak Chopra and Tayur N. Guru Row</i>	
3.1	Introduction	29
3.1.1	Co-crystals and Salts	31

3.2	Role of Intra- and Intermolecular Interactions	32
3.2.1	Halogen...Halogen Interactions	32
3.3	Debate on Organic Fluorine	34
3.3.1	Topological Analysis of the Electron Density of Compounds Containing Organic Fluorine: Insights from Experimental and Theoretical Electron Density Analysis	35
3.4	Conclusions	38
	Acknowledgement	39
	References	39
<b>Chapter 4</b>	<b>Polymorph Prediction of Small Organic Molecules, Co-crystals and Salts</b>	<b>44</b>
	<i>Frank J. J. Leusen and John Kendrick</i>	
4.1	Introduction	44
4.1.1	Relevance of Crystal Structure Prediction	44
4.1.2	Historic Overview	45
4.2	Theory of Crystal Structure Prediction	47
4.2.1	Lattice Energy Calculations	47
4.2.2	Searching for Potential Structures	55
4.3	Application Examples	61
4.3.1	Blind Tests of Crystal Structure Prediction	61
4.3.2	Co-crystals	67
4.3.3	Solvates	73
4.3.4	Salts	76
4.4	Outlook	82
	References	83
<b>Chapter 5</b>	<b>Shape and Polarity in Co-crystal Formation: Database Analysis and Experimental Validation</b>	<b>89</b>
	<i>L. Fábrián and T. Friščić</i>	
5.1	Introduction	89
5.2	Database Analysis of Molecular Properties in Co-crystals	92
5.2.1	Compilation of the Co-crystal Database	92
5.2.2	Statistical Analysis	93
5.2.3	Results and their Interpretation	93
5.3	Experimental Testing of Shape and Polarity Preferences	97
5.3.1	Co-crystal Screening Methods	98
5.3.2	Prioritising Screening Experiment by Molecular Descriptors	99
5.3.3	Combined Effect of Synthons and Shape	102
5.3.4	Identification of New Intermolecular Interactions	104

5.4	Conclusions	108
	Acknowledgements	108
	References	108
<b>Chapter 6</b>	<b>Role of Co-crystals in the Pharmaceutical Development Continuum</b>	<b>110</b>
	<i>Nate Schultheiss and Jan-Olav Henck</i>	
6.1	Introduction	110
6.2	Common Solid-state Strategies for API Property Modification	111
6.3	Co-crystals and their Characterization	112
6.4	Co-crystals and their Role in the Pharmaceutical Development Process	113
6.5	Using Co-crystals to Alter Physicochemical Properties of APIs	115
	6.5.1 Stability	115
	6.5.2 Solubility	116
	6.5.3 Bioavailability	119
6.6	Additional Development Factors for Co-crystals	121
	6.6.1 Taste Masking	121
	6.6.2 Scale-up	123
	6.6.3 Polymorphism	123
6.7	Conclusions	124
	Acknowledgement	125
	References	125
<b>Chapter 7</b>	<b>Solid Forms and Pharmacokinetics</b>	<b>128</b>
	<i>N. Biswas</i>	
7.1	Introduction	128
	7.1.1 Impact of Solid Form on the Pharmacokinetics	131
	7.1.2 Important PK Parameters	133
7.2	Dissolution and Solubility	135
	7.2.1 Effect of dissolution on absorption	136
	7.2.2 Impact of Dissolution Rate on Bioavailability	137
	7.2.3 Case Studies Demonstrating the Relationship Between Dissolution Rate and Bioavailability	138
	7.2.4 Adverse Effects	141
7.3	Significance of Altered Dissolution Properties	142
	7.3.1 Case Studies	142
7.4	Selection of Solid Form Based on the Therapeutic Condition: Case Study of Indinavir	144
7.5	Manipulation of the Pharmacological Action of a Drug by Co-Crystallization: Case Study of Insulin	146

7.6	Toxicity Caused by Co-crystal Formation	149
7.7	Conclusion	150
	References	151
<b>Chapter 8</b>	<b>Application of Mechanochemistry in the Synthesis and Discovery of New Pharmaceutical Forms: Co-crystals, Salts and Coordination Compounds</b>	<b>154</b>
	<i>Tomislav Friščić and William Jones</i>	
8.1	Introduction	155
8.2	Historical Overview	155
8.3	Overview of Mechanochemical Methodologies	157
8.3.1	Comparison with Solvent-based Co-crystallisation Techniques	157
8.3.2	Screening for Co-crystals Using Neat and Liquid-assisted Grinding	159
8.3.3	Control of Polymorphism Using Mechanochemistry	161
8.3.4	Control of Co-crystal Stoichiometry Using Mechanochemistry	162
8.4	Examples of Pharmaceutical Co-crystal Synthesis and Screening Using Mechanochemistry	165
8.5	Mechanistic Aspects of Co-crystal Mechanosynthesis	168
8.5.1	Mass Transfer Mediated by a Vapour Phase	168
8.5.2	Mechanochemical Co-crystallisation Mediated by a Eutectic	170
8.5.3	Mechanochemical Co-crystallisation Mediated by an Amorphous Phase	172
8.5.4	Kinetic Effects in the Mechanosynthesis of Co-crystals	173
8.6	Three-component Pharmaceutical Solids	175
8.6.1	Chiral and Racemic Co-crystals and Co-crystal-Co-crystal Reactions	175
8.6.2	Co-crystal Hydrates	176
8.6.3	Host–guest systems	178
8.7	Mechanochemical Synthesis of Pharmaceutical Salts	179
8.8	Mechanochemical Synthesis of Metal–Organic Pharmaceutical Derivatives	180
8.9	Conclusions	182
	Acknowledgements	182
	References	183

<b>Chapter 9</b>	<b>Co-crystallization in Solution and Scale-up Issues</b>	<b>188</b>
	<i>E. Gagnière, D. Mangin, S. Veessler and F. Puel</i>	
9.1	Introduction	188
9.2	Concepts and Phenomenon Involved in a Co-crystallization Process in Solution	189
9.2.1	Supersaturation	189
9.2.2	Nucleation	190
9.2.3	Crystal Growth	190
9.2.4	Dissolution	191
9.2.5	Metastable Phases and their Transition: Solution-mediated Phase Transition (SMPT)	192
9.3	Thermodynamic and Kinetic Aspects of a Co-crystallization Process	193
9.3.1	Phase Diagram	194
9.3.2	Relative Stability of the Solid Phases in Solution	195
9.3.3	Kinetic Pathways in a Phase Diagram	197
9.4	Development of a Co-crystallization Process	204
9.4.1	Prerequisite	204
9.4.2	Co-crystal Screening	205
9.4.3	Determination of Operating Conditions in Batch Mode	206
9.4.3.1	Choice of “Safe” Operating Regions (Initial Conditions and Phase Diagram)	207
9.4.3.2	Seeding Strategy	207
9.4.3.3	Manipulation of Co-crystal Components	208
9.5	Conclusions	208
	Acknowledgements	209
	References	209
<b>Chapter 10</b>	<b>Analytical Techniques and Strategies for Salt/Co-crystal Characterization</b>	<b>212</b>
	<i>Susan M. Reutzler-Edens</i>	
10.1	Introduction	212
10.2	Analytical Techniques	213
10.2.1	X-ray Diffraction	214
10.2.2	Thermal Analysis	216
10.2.3	Microscopy	219
10.2.4	Vibrational (Raman, IR) Spectroscopy	222
10.2.5	Solid State NMR Spectroscopy	223
10.2.6	Moisture Sorption Analysis	226

10.3	Integrated Approaches to the Solid State	227
	Characterization of Salts and Co-crystals	228
10.3.1	Form Identification/Phase Purity	231
10.3.2	Proton Transfer in the Solid State	237
10.3.3	Thermodynamic Stability	242
10.3.4	Storage and Process-induced Phase Transformations	243
10.4	Conclusions	243
	References	243
<b>Chapter 11</b>	<b>Co-crystal Solubility and Thermodynamic Stability</b>	<b>247</b>
	<i>L. Roy, M.P. Lipert and N. Rodriguez-Hornedo</i>	
11.1	Introduction	247
11.2	Co-crystal Solubility	248
11.2.1	Key Concepts	248
11.2.2	Factors that Influence Solubility	250
11.3	Tailoring Co-crystal Solubility via Solution Phase Chemistry	253
11.3.1	Ionization	254
11.3.2	Micellar Solubilization	259
11.4	Co-crystal Thermodynamic Stability and Solubility Evaluation	268
11.4.1	Co-crystal Thermodynamic Stability	272
11.5	Eutectic Point Measurement	273
11.6	Co-crystal Solubility Measurement	273
11.6.1	Thermodynamic Equilibrium Methods	275
11.6.2	Kinetic Methods	276
11.7	Conclusions	276
	References	276
<b>Chapter 12</b>	<b>Application of Phase Diagrams in Co-crystal Search and Preparation</b>	<b>280</b>
	<i>Timo Rager and Rolf Hilfiker</i>	
12.1	Introduction	281
12.2	Binary Phase Diagrams	284
12.3	Thermodynamic Selection Criteria for Co-crystal Formers	285
12.4	Ternary Phase Diagrams	289
12.5	Thermodynamic Selection Criteria for Suitable Preparation Conditions	291
12.6	Possible Failures in Co-crystal Search	

<i>Contents</i>	xiii
12.7 Phase Diagrams for Most Efficient Co-crystal Search	293
12.8 Phase Diagrams for Optimized Co-crystal Preparation	295
12.9 Conclusion	297
Further Reading	297
<b>Chapter 13 Limits of the Co-crystal Concept and Beyond</b>	<b>300</b>
<i>Gerard Coquerel</i>	
13.1 Most Frequent Heterogeneous Equilibria Related to Co-crystals	300
13.2 Compounds that could be Defined as Hybrid Salt–Co-crystals	303
13.2.1 Example 1: Resolution of Fenfluramine	305
13.2.2 Example 2: Trimebutine Maleate	305
13.2.3 Example 3: a Hybrid Salt–Co-crystal	305
13.3 Co-crystals of ‘Alike’ Molecules (including Enantiomers, Isomers, Diastereomers ...)	306
13.4 Host–guest Compounds: Co-crystals at least Partially Driven by Inclusion Phenomena at the Molecular Level	311
13.5 Conclusions	314
Acknowledgements	315
References	315
<b>Chapter 14 Co-crystals: Commercial Opportunities and Patent Considerations</b>	<b>318</b>
<i>Marcel Hoffman and Jeffrey A. Lindeman</i>	
14.1 Introduction	319
14.2 Co-crystals – Engineering Pharmaceutical Properties/Creating Commercial Value	319
14.3 Definition of a Co-crystal	321
14.4 Patentability of Co-crystals	323
14.5 Information for Effective Co-crystal Patents	325
14.6 Conclusions	327
References	328
<b>Chapter 15 Concluding Remarks using Piracetam as a Learning Model</b>	<b>330</b>
<i>Johan Wouters, Anaëlle Tilborg and Luc Quéré</i>	
References	336



<b>Chapter 16 Monographs of most Frequent Co-Crystal Formers</b>	<b>338</b>
<i>Johan Wouters, Sandrine Rome and Luc Quéré</i>	
16.1 Introduction	338
16.2 Monographs on Co-crystal Formers	340
Acknowledgements	340
References	377
<b>Subject Index</b>	<b>383</b>